Mao W - Search Results

1

Enhanced expression of cohesin loading factor NIPBL confers poor prognosis and chemotherapy resistance in non-small cell lung cancer.

Xu W, Ying Y, Shan L, Feng J, Zhang S, Gao Y, Xu X, Yao Y, Zhu C, Mao W. Xu W, et al. Among authors: mao w. J Transl Med. 2015 May 12;13:153. doi: 10.1186/s12967-015-0503-3. J Transl Med. 2015. PMID: 25963978 Free PMC article.

2

Inhibition of NIPBL enhances the chemosensitivity of non-small-cell lung cancer cells via the DNA damage response and autophagy pathway.

Zheng L, Zhou H, Guo L, Xu X, Zhang S, Xu W, Mao W. Zheng L, et al. Among authors: mao w. Onco Targets Ther. 2018 Apr 5;11:1941-1948. doi: 10.2147/OTT.S158655. eCollection 2018. Onco Targets Ther. 2018. PMID: 29670369 Free PMC article.

3

The transcription factor c-Jun regulates Smad4 expression by upregulating pre-miR-183 expression to promote invasion and metastasis of esophageal squamous cell carcinomas.

Xu X, Zheng L, Hang N, Zhu G, Mao W, Fan Y, Tao K. Xu X, et al. Among authors: mao w. In Vitro Cell Dev Biol Anim. 2020 Aug;56(7):550-558. doi: 10.1007/s11626-020-00499-6. Epub 2020 Aug 28. In Vitro Cell Dev Biol Anim. 2020. PMID: 32886291

4

Tumor Microenvironment-Associated Immune-Related Genes for the Prognosis of Malignant Pleural Mesothelioma.

Xu X, Cheng L, Fan Y, Mao W. Xu X, et al. Among authors: mao w. Front Oncol. 2020 Sep 16;10:544789. doi: 10.3389/fonc.2020.544789. eCollection 2020. Front Oncol. 2020. PMID: 33042835 Free PMC article.

5

Clinical features and prognosis of resectable pulmonary primary invasive mucinous adenocarcinoma.

Xu X, Shen W, Wang D, Li N, Huang Z, Sheng J, Rucker AJ, Mao W, Xu H, Cheng G. Xu X, et al. Among authors: mao w. Transl Lung Cancer Res. 2022 Mar;11(3):420-431. doi: 10.21037/tlcr-22-190. Transl Lung Cancer Res. 2022. PMID: 35399567 Free PMC article.

6

Liquid chromatography-mass spectrometry based metabolic characterization of pleural effusion in patients with acquired EGFR-TKI resistance.

Li N, Mao W, Gao Y, Wang D, Song Z, Chen Z. Li N, et al. Among authors: mao w. J Pharm Biomed Anal. 2021 Aug 5;202:114147. doi: 10.1016/j.jpba.2021.114147. Epub 2021 May 18. J Pharm Biomed Anal. 2021. PMID: 34029974

7

A novel PDX modeling strategy and its application in metabolomics study for malignant pleural mesothelioma.

Chen Z, Yang C, Guo Z, Song S, Gao Y, Wang D, Mao W, Liu J. Chen Z, et al. Among authors: mao w. BMC Cancer. 2021 Nov 17;21(1):1235. doi: 10.1186/s12885-021-08980-5. BMC Cancer. 2021. PMID: 34789172 Free PMC article.

8

Metabolomics of a cell line-derived xenograft model reveals circulating metabolic signatures for malignant mesothelioma.

Gao Y, Dai Z, Yang C, Wang D, Guo Z, Mao W, Chen Z. Gao Y, et al. Among authors: mao w. PeerJ. 2022 Jan 4;10:e12568. doi: 10.7717/peerj.12568. eCollection 2022. PeerJ. 2022. PMID: 35036082 Free PMC article.

9

Impact of alcohol dehydrogenase gene 4 polymorphisms on esophageal squamous cell carcinoma risk in a Chinese population.

Xu X, Wang J, Zhu SM, Yang M, Fang Y, Zhao A, Song Q, Mao W. Xu X, et al. Among authors: mao w. PLoS One. 2015 Jun 3;10(6):e0127304. doi: 10.1371/journal.pone.0127304. eCollection 2015. PLoS One. 2015. PMID: 26039424 Free PMC article.

10

Tissue-based metabolomics reveals metabolic biomarkers and potential therapeutic targets for esophageal squamous cell carcinoma.

Chen Z, Gao Y, Huang X, Yao Y, Chen K, Zeng S, Mao W. Chen Z, et al. Among authors: mao w. J Pharm Biomed Anal. 2021 Apr 15;197:113937. doi: 10.1016/j.jpba.2021.113937. Epub 2021 Feb 5. J Pharm Biomed Anal. 2021. PMID: 33609949

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

3,041 results

Search Page

Filters